• A L Zietman, E A Prince, B M Nakfoor, and W U Shipley.
• Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
• Urology. 1997 Mar 1; 49 (3A Suppl): 74-83.

AbstractConventional radiotherapy has been a standard treatment for the management of locally advanced T2c-4 prostatic carcinoma for over 2 decades. The routine use of serum PSA in follow-up makes it clear that > 80% of these patients will show evidence of failure by 10 years. Rebiopsy of those with a rising PSA shows locally persistent disease in the majority of cases. Increasing the radiation dose applied to the prostate increases local control but at the risk of higher morbidity. Experimental data using the Shionogi tumor mouse model suggest a potential gain from neoadjuvant androgen suppression without any increase in normal tissue morbidity. Two randomized trials comparing neoadjuvant androgen suppression prior to radiation therapy with radiation alone in humans show considerable short-term gains in local control and disease-free survival but mature data are still awaited. It is currently unknown whether the positive interaction between radiation and androgen suppression is synergistic or simply additive.

22 keywords...

hide…